Schedule an Appointment
Kalos Therapeutics Inc

Kalos Therapeutics Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

 

 

 

 

Book a Conference Call
Get More Information

Kalos Therapeutics Inc

Location: Phoenix, AZ

Sector: Life Sciences.

Add to Shortlist
Express Interest

Kalos Therapeutics, Inc. is a biomedical company developing a class of therapeutic peptides to fight cancer.  These peptides have already shown significant clinical activity in cardiovascular, cancer and veterinary indications. Kalos’ drugs replicate a natural, anti-proliferative activity by disrupting tubulin activity.

Our lead drug candidate, KTH-222, is a safe, non-toxic drug which may be used as 1) a front-line therapy, 2) a long-term maintenance therapy or 3) a co-therapy which reduces time to chemo resistance and minimizes chemo side-effects.  KTH-222 reduces tumor size while addressing complications, such as metastasis, thereby, allowing the patient to maintain a quality of life not seen with chemo therapy treatments alone.

Initial cancer markets include:  pancreatic, ovarian, prostate, lung and liver.  An animal division will develop drugs for the treatment of cancer and renal disease, congestive heart failure and epistaxis.

Business Documents

MG cp Summary

KTH-222 – Human Cancer

Breakthrough technology – Novel therapeutic for unmet medical need in pancreatic cancer and associated complications like metastases.

 

Orphan Drug Designation – U.S. Orphan designation qualifies the sponsor to a seven-year period of market exclusivity upon approval of the drug. Sponsor may apply for FDA orphan research grants, a waiver of Prescription Drug User Fee Act filing fees andtax credits for clinical research costs.

 

Low to no toxicity, well tolerated and limited to no side effects – Our drug could be used as a lead therapy, a second line active therapy or potentially the first long-term maintenance therapy for many cancers.  Based on its low/no toxicity, there is little risk of resistance and when used in combination, chemo amounts can be reduced with an improved quality of life for the patient.

 

KTH-222/variants – Canine Cancer

Pet owners are reluctant to subject their pets to chemotherapy based on Quality of Life (QOL), costs, and outcomes. KTH-222 is well tolerated, fewer, if any side effects, reduces primary tumor, address complications like metastases, improves QOL and can be used in combination with chemo should the owner desire.

 

KTH-222/variant – Retinal disease

Ease of delivery – Kalos has explored delivery of this therapy in retinal disease as a topical, delivered as a viscous drop, or applied to film. The goal is to eliminate or reduce injections into the eye as site fatigue is a problem and compliance of patients is difficult. This approach can be adapted in multiple eye diseases and KTH-222 should follow the pathway of testing previously completed with the parent peptide where vision was restored in AMD simulated animal models.

 

KTV-111 – Animal Epistaxis, Equine athletes

Focused on fluid removal to reduce bleeding in Equine Athletes – A well tolerated, potassium sparing approach to fluid removal to stop bleeding, additive benefits: regeneration of microtubules, and improvement of compromised heart function providing therapeutic benefits to the horses, while being compliant with regulations in each sport or event.

Quality-of-Life Safer, less toxic approach to slowing cancer with fewer side effects.

 

Safety/Toxicity Well tolerated. It is similar to amino acids found in the heart.

 

Addresses metastasis Our drug recognizes the metastasis and attacks these as small tumors.  This is not being addressed by other therapies, and can lead to a long-term maintenance therapy and increased survival.

 

Synergistic Can be used in conjunction with existing therapies to provide a better quality-of-life and progression free survival.

 

Reduction of drug resistance When used synergistically with chemo, the amount of chemo used can be reduced thereby allowing a longer treatment cycle.

George Colberg, Co-Founder, CEO, Chairman

Mr. Colberg is a seasoned corporate finance and management executive. He was CEO of Primary Inc., a company where he pioneered the plan for acquisitions and the business model initiating early efforts in personalized medicine, electronic medical record meshed with patient data and billing and the advanced use of diagnostics. Prior to Primary Care he was a Vice President at the Financial Group managing syndications and equity investment research while raising in excess of $100 million.

 

Mr. Colberg developed the corporate philosophy of Kalos, identified and shaped the strategy behind the primary products, and the commercialization plan for Kalos. He raised the seed round, series A and B rounds and grant financing totaling $3.5 million. He recruited the executive team and scientific advisory board and oversees the clinical development plan.  Mr. Colberg set the strategy for securing US and EU IP patents and the Orphan Drug Designation.

 

Mr. Colberg completed his Bachelor of Science from San Diego State University and attended University California, Berkeley  for a Certification as a Biomedical Executive.

 

Jay Merritt, MD, President and Chief Medical Officer

Dr. Merritt is a medical oncologist with over 20 years’ experience as a biotechnology executive. He most recently served as President and Chief Medical Officer at Adventrx Pharmaceuticals.  He was founding CEO of Imagine Pharmaceuticals, a venture stage company with a small molecule approach to facilitate drug uptake across the blood brain barrier.

 

He began his industrial career at the Upjohn Company leading early stage oncology and infectious diseases clinical research and he played a key role in launching Upjohn’s HIV research program. He subsequently held senior management positions at IDEC Pharmaceuticals (now Biogen Idec), Viagene Inc. and Introgen Therapeutics, successfully advancing ground-breaking biological modalities such as therapeutic monoclonal antibodies for cancer and rheumatologic diseases, and retroviral and adenoviral gene transfer technologies for cancer and HIV.

 

Dr. Merritt graduated from Johns Hopkins University and received an M.D. from the University of Vermont. He trained in Internal Medicine and Medical Oncology at the University of Wisconsin where he was also appointed Assistant Scientist in the Biophysics Laboratory.

 

Michael Kozlowski, PhD, Chief Science Officer

Dr. Michael Kozlowski is an Associate Professor at the Arizona College of Optometry (AZCOPT) at Midwestern University and CSO at Kalos therapeutics. Prior to Kalos, Dr. Kozlowski spent over 25 years in drug discovery and development for several clinical applications including cancer, age-related macular degeneration, and CNS disorders, and has over 40 peer-reviewed publications and over a dozen issued US patents.

 

He has worked with large pharmaceutical (Pfizer, BMS) and biotechnology companies (Geron, Telik, Axiom, Kreido Laboratories).  Dr. Kozlowski has held positions ranging from Research Scientist to Chief Scientific Officer.

 

Dr. Kozlowski holds a BS in Biology from Caltech, a PhD in Neuroscience from the University of California at Irvine, and an OD from the New England College of Optometry.


uShip, Inc

uShip, Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

 

 

 

 

 

Book a Conference Call
Get More Information

uShip, Inc

Location: Austin, Texas

Sector: Logistics.

Add to Shortlist
Express Interest

As featured on the A&E hit reality show “Shipping Wars”, privately-held uShip (www.uShip.com) is a the world’s first and largest online shipping marketplace. uShip’s platform has enabled millions of customers and businesses to ship almost any category of large items such as freight, household goods, vehicles, and heavy equipment.

 

uShip’s dynamic spot marketplace allows customers to review and book with hundreds of thousands of transportation providers that can range from independent owner-operators to the world’s largest fleets, carriers and freight brokers.

 

Founded in 2003, uShip is headquartered in Austin, TX but operates globally with localized sites in 19 countries and regions on six continents. uShip is backed by the world’s most prestigious VC’s (Benchmark Capital, Kleiner-Perkins) and DB Schenker, the world’s third largest 3PL (2015).

Business Documents

MG cp Summary
  • 2014 revenue: $139 MM
  • 2015 revenue: $160 MM
  • 2016 revenue: $178 MM
  • Revenue growth rate: 11.3%
  • Employee growth rate: 9%
  • Jim Martell, who has been the Chairman of multiple extremely successful logistics companies, has recently become Chairman of the Board.

Total funding raised to date is $52.8 MM

 

  • June 2005: Benchmark invests $2.7 MM
  • October 2006: Benchmark and DAG Ventures invests $5.1 MM
  • February 2011: Benchmark invests $2 MM
  • December 2012: Kleiner, Perkins, Caufield & Byers (KPCB) invests $18 MM
  • February 2017: Db Schenker Rail (UK) Limited invests $25MM
  • uShip, the logistics technology company, today announced it has launched an in-home delivery service for e-commerce merchants selling large, heavy goods online.
  • The company also says its delivery volume has doubled over the past three years.
  • uShip’s successful pilot program with online seller Everything But The House (EBTH), the world’s premier online marketplace for authenticated second-hand items, and other e-commerce merchants processed over 12,000 fixed-price furniture deliveries to customers across the United States.
  • Partners reported cutting delivery costs by nearly 50 percent, and reducing transit times by up to 65 percent, from 4-6 weeks to just 14 days.
  • On uShip, a new shipment is posted every 20 seconds
  • uShip’s less-than-truckload (LTL) instant rate platform has seen 52 percent annual transaction growth.
  • Since 2004, uShip’s marketplace has facilitated the delivery of more than 2.2 million oversized items.

Petrics

Petrics

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Petrics

Location: Wilmington, NC

Sector: Technology.

Add to Shortlist
Express Interest

Petrics is a pet technology company that develops IoT products and associated software that empower pet owners to properly manage, track and respond to their pet’s health and nutrition needs in a timely, convenient and cost-effective manner.

We are developing an ecosystem of connected products that are easily controlled by popular mobile and smart home devices to track critical pet health data, so pets live longer, happier, healthier lives.

  • Nutrition Recommendation Engine + Food Allergy profile
    First to have true diet and nutrition recommendation engine for the pet industry. Can pair your pet with ideal foods and treats based on their personalized needs with our exclusive ingredient breakdowns and breed database.  We are also adding the food allergy testing so we can be the first to ever offer personalized nutrition with thousands of foods in the market and automatically filter based on thousands of ingredient food tolerances based on the profile. This is a game changer for the pet food industry.
  • Smart Pet Bed and Pet Health Ecosystem
    A true pet health ecosystem that is the first to use a pet bed to provide veterinarians and pet owners with up to date weight monitoring to spot health issues early.  Vets love this since they only get to check weight every 6 months to a year.  This gives them the consistent and frequent feedback loop they have been looking for since pet owners do not provide the most up to date or reliable feedback in order to make better, more informed recommendations or adjustments to their treatments.
  • Family and pet management tool
    Our app allows pet owners, family members, and other service professionals to share critical information to help manage their pet’s health, feeding and medicine schedules, and appointment scheduling.
  • World’s first smart pet bed and Issued Patent
    First to market with a smart bed system.
  • App accesses 15k foods & treats and 17k ingredients
    Petrics has worked with veterinarians and pet nutritionists at NC State to validate our database of ingredients, foods and treats. We have created the first food recommendation engine that takes each pet’s unique characteristics into consideration when selecting food options. This takes into account the pet’s breed, age, weight, existing health issues, food allergies, and genetic risks into consideration when identifying the ideal food or treat options.
  • We have an exclusive partnership with Affordable Allergy Test
    This partnership allows us to offer allergy test ordering directly through our app, providing allergy results that will tie directly into the decision process when determining the ideal foods and treats. This is a game-changer in the industry.
  • Bed has built in scale
    Veterinarians are excited about the built-in scale so weight fluctuations may be monitored more closely, raising the red flag when pet may be at risk of serious underlying health issues. Also, when used in conjunction with the activity tracker and companion app, proper weight may be monitored based on calorie intake with certain foods and calorie burn, as provided through the tracker.
  • Bed has climate control (first mover)
    First in market to offer Conductive heating and cooling capabilities keep pets with thick coats cool during hot summer days, minimizing the chance of heat stroke, all while warming pets during the cold of winter. Climate control is also ideal for geriatric pets or those recovering from an injury.
  • Accessibility& simplicity
    Easy to set up, customize and monitor all pets within the app. Perfect for today’s busy pet parents.

Edward Hall, Founder & CEO/ BOD Member

Edward Hall is NAVY Veteran and graduate of the Cameron School of Business Entrepreneurship and Business Development program at the University of North Carolina at Wilmington. During his years in the service as a technical supervisor, he directed operations of anti-ship missile defense systems. Edward spent nearly two years at Elite Innovations, a Makerspace and engineering product development firm, where he helped start and grow the company while leading teams in the design and development of over thirty products that ranged from general consumer products to high-tech IoT life support systems.

 

His diverse experience with developing new products and commercializing them throughout various markets, coupled with his entrepreneurial drive, helped motivate his desire to start Petrics, Inc. in 2015, when he saw the need for improving pet health and nutrition first hand through his experience with his mother’s pets. Today, his passion has transformed into a reality with Petrics, as he strives to make a difference in the health and well-being of our pets, so they live longer, happier lives.

 

Kristopher Johnson, Director of Sales & Marketing

Kris brings over 26 years of diverse marketing experience in corporate strategy, product development, brand management, communications and business development. Kris has built and mentored cohesive teams to deliver an all-inclusive sales and marketing package to numerous markets, including healthcare, technology, technical materials and sporting goods.

 

Kris has worked with healthcare companies such as, Masimo Corporation, Gaymar Industries, Stryker Medical, Reichert Technologies and AccuMed Technologies, and has a complete understanding of what is required to market products both domestically and internationally. His experience in technology while working with ATTO, forged a deep understanding of developing effective distribution channels worldwide and ensuring that each channel partner achieves all expectations and revenue goals.

 

As a product manager with Gaymar Industries, Kris oversaw the P&L of a $38MM product line that he grew 22% overall and played an integral role in the corporate exit strategy and eventual acquisition by his top OEM customer, Stryker Medical.

 

Ryan Roberts , Product Manager & Project Manager

Ryan Roberts brings over 30 years of demonstrated experience in Project Management and Product Engineering to the Petrics’ team. A dedicated problem solver, Ryan has successfully directed the development, manufacturing and overall commercialization process within world class organizations, like Accenture, AT RAMAR and Sensus. His vast experience in cloud-based analytics software, mobile work packages and hardware design & development integrates perfectly with the Petrics ecosystem and ensures accurate and timely delivery of products.

 

In addition to his vast experience, Ryan is also the Co-Founder of The Blue Water Group, Inc., a Management Consulting firm helping manufacturing organizations LAUNCH, GROW and SUCCEED by providing Manufacturing, Quality Management, Engineering, Supply Chain, Auditing, Training and Process Improvement. Ryan is an asset to the future success of Petrics and will play an integral role in achieving anticipated manufacturing and commercialization expectations.

 

Mandy Miller, Director of Customer Experience (CX)

Formerly as Ten8Tech”s director of client engagement, Mandy Miller directed key partnerships developed strong relationships at every touch-point throughout the customer’s interaction with the company. Prior toTen8Tech, she enjoyed two years with beverage data app company Next Glass, and their beer app Untappd. She helped launch the company and Next Glass hit 100k downloads in 2 days and were featured by Apple. Ten days later, that jumped to 250k downloads. Mandy began directing social media, progressed to client success manager and ultimately manager of customer engagement.

 

Rich Slevin, Board of Directors Member

Rich is a developer and manufacturer of over 250 consumer, commercial, military and medical electronic products since 1993. He has been leading and innovating new technologies and products at the rate of a dozen a year for OEM customers. Rich has also incubated over a dozen startup companies as well as spin offs and company buyouts and is an active angel investor and advisor.

 

Rich’s background includes advancing engineering and executive level positions at BF Goodrich, Raychem, Kyocera and others before starting ODI. In 2008, Rich started a spinoff company, Spracht, to address the emerging teleconferencing and video conferencing markets.  In 2013, with a partner, Rich orchestrated the purchase of an IoT company focused on wireless monitoring in buildings.

 

Ted Coughlin, Board of Directors Member

Ted started his career by working for the Navy in Newport, RI performing research and development for submarines and undersea warfare systems.  He spent most of his career in the Washington DC region working in engineering, management and senior management positions.  His expertise was in the acquisition of next generation Intelligence, Surveillance and Reconnaissance Systems for the Department of Defense and Intelligence Community.

 

He managed the Tactical Systems Directorate at the Aerospace Corporation and was Senior Vice President at ElanTech Systems. Ted provided executive, technical and project management expertise in the successful development of 50+ systems/products ranging in cost from $2M to $2.5B.


Protected: RxConcile

Protected: RxConcile

This content is password protected. To view it please enter your password below:

Voujo

Voujo

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Voujo

Location: San Diego, CA

Sector: Software.

Add to Shortlist
Express Interest

Voujo is a dating app that connects people through personality-based feedback provided by other members and a member’s friends.

Voujo is the only dating app that lets you filter potential dates by desirable personality traits. Then, see what a person’s friends say, and other members who have interacted with the person, before deciding whether to chat or meet up. The net effect: you only write part of your own profile. The rest is written by others.

Business Documents

MG cp Summary

Validated User Acquisition

In our space, initial user acquisition is the largest hurdle faced by a startup. Various factors force a startup to engage in a localized, grassroots effort to acquire an initial user base that will allow the app to operate on its own without people running out of matches. Validating an initial user acquisition method is very difficult.

But once it is done, all a startup needs to do is scale it and the company is in serious business. Borrowing from the methods utilized successfully in our space, we have validated just such a method, and it can be scaled in a big way.

 

Profitable

Building the initial mass of users necessarily requires taking a loss initially, but due to our planned lean operation, as well as our unique and multiple revenue streams, we anticipate achieving profitability (a rarity in our industry, which focuses more on users) relatively quickly and, perhaps as important, amassing a large amount of cash on hand that can be used in a variety of ways and will lessen the need to fund-raise as often as most startups, much less dating services.

 

Portability of Technology

Because our key features are specifically planned to not be inherent to a dating service, they will be portable. In other words, they can be used to start other business lines, particularly once we achieve a mass of users and data we can transfer over to a new, related business, thereby avoiding altogether initial customer acquisition.

First Impression Feedback

Once a certain level of interaction has been achieved between two users, each can provide personality-based, anonymous feedback. The available choices are all positive and are the particular personality traits people most want to see in a potential date out of the gate (e.g., smart, funny, nice). This feedback is displayed on a member’s profile in summary form and can be seen by those other members the member chooses to interact with.

 

Friend Feedback

A user can solicit up to 3 friends to provide them a narrative endorsement that is placed on the user’s profile. This feedback is displayed on a member’s profile in summary form & can be seen by those other members the member chooses to interact.

 

Personality Trait Searches

A member can choose as one of his or her search filters the personality traits related to First Impression Feedback. Because of the obviously/intentionally biased nature of Friend Feedback it is not incorporated into the search algorithm.

 

Control of Interaction

No one can see your full profile or message you unless you choose to let them. So if someone likes you, that person cannot do either of those things unless you like the person back or send them a message. You can remove this access at any time

Matt Wiles, Co-Founder

Matt places much of his focus on business, financial, legal, and strategy issues, and assists as needed with other areas. As a lawyer, he has been representing the legal interests of sophisticated businesses for over 15 years. Currently a Partner in an AmLaw 200 firm, Matt maintains an office and client base both in Ohio and California.

Serving in a first- chair, client-facing capacity, so his work largely consists of development and execution of both legal and business strategies; business, financial, securities/fundraising-related and legal issues.

Matt was named a Rising Star by SuperLawyers Magazine and served as primary outside litigation counsel for multi-billion dollar company, representing company’s interests across country.

 

Kyle Gernhofer, Co-Founder

Kyle focuses his efforts on the creative evolution of the product, based on user and other feedback as well as the competitive landscape, and including interfacing with developers and designers.

Kyle was selected as a recipient for the Health Professions Scholarship Program (HPSP) by the US Navy Dental Corps. As the Chief Dental Officer aboard the USS TORTUGA, Kyle was awarded the prestigious Navy Commendation Medal in 2008 for executing a multi-national exercise in Thailand, Philippines and Malaysia, providing free dental care to over 1000 people in need.

He was also recognized as maintaining the highest dental readiness numbers of any Dental Officer in the United States Naval Fleet. Today, he helps run one of the busiest and most respected dental offices in San Diego County.

 

Meghan Brohoski, Marketing/User Acquisition

Meghan’s strengths are content marketing, partnerships, communication and social media. Her background with startups has taught her how to be scrappy, data-driven, and resourceful. Meghan, a former sorority member, heads and manages our college program.

In addition to Voujo, Meghan is also a Community Manager at a health and fitness tech startup based in San Diego. As a member of a Marketing team of two, she wears many different hats: managing the companies social media, influencer marketing, partner relations, events, vendor prospecting, email marketing, content marketing, customer feedback, and more.